Get the Stockscreener App
131.42
4.52%
-6.22
Protagonist Therapeutics Inc stock is traded at $131.42, with a volume of 954.57K.
It is down -4.52% in the last 24 hours and up +24.25% over the past month.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$137.64
Open:
$137.12
24h Volume:
954.57K
Relative Volume:
1.34
Market Cap:
$8.45B
Revenue:
$74.06M
Net Income/Loss:
$-114.71M
P/E Ratio:
-72.85
EPS:
-1.8039
Net Cash Flow:
$-117.90M
1W Performance:
-0.15%
1M Performance:
+24.25%
6M Performance:
+63.82%
1Y Performance:
+148.78%
1-Day Range:
$130.64
$137.12
1-Week Range:
$128.15
$141.10
52-Week Range:
$50.48
$141.10
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
131.42 | 8.45B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Protagonist Therapeutics (PTGX) AGM 2026 Summary - Quartr
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued - Yahoo Finance
Liquidity Mapping Around (PTGX) Price Events - Stock Traders Daily
New Strong Buy Stocks for July 9th - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest - simplywall.st
Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review FocusHas The Bull Case Changed? - Yahoo Finance
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains? - Yahoo Finance
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Protagonist Therapeutics (PTGX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
PTGX climbs as target hike adds to late-stage pipeline optimism - Quiver Quantitative
PTGX Stock Grinds Higher As Pipeline Catalysts Build - StocksToTrade
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com India
Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies - ad-hoc-news.de
Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally - AlphaStreet
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? - TradingView
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $145 - Moomoo
PTGX Maintained by Truist Securities -- Price Target Raised to $145.00 - GuruFocus
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com
Price to sales forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX - TradingView
Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating - Moomoo
Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD - Investing.com
PTGXProtagonist Therapeutics Inc Volatility & Greeks - Finviz
Protagonist Therapeutics updates its pipeline. PTGX focuses on peptide drug development - ad-hoc-news.de
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock - Yahoo Finance
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics awards new hires stock options and RSUs - Stock Titan
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Why (PTGX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 4 Protagonist Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
Protagonist Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTGX) - TradingView
Protagonist Therapeutics director Waddill sells $1.06m in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics director Waddill sells $1.06m in stock - Investing.com
Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan - Stock Titan
Protagonist Therapeutics stock hits all-time high at 124.97 USD By Investing.com - Investing.com South Africa
PTGX Forecast — Price Target — Prediction for 2027 - TradingView
Protagonist Therapeutics stock hits all-time high at 124.97 USD - Investing.com
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Why Is Silence Therapeutics Stock Soaring Wednesday?Silence Therapeutics (NASDAQ:SLN) - Benzinga
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest - Sahm
Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
PTGX (NASDAQ) Form 144: Director-linked 9,000-share sales and option exercise - Stock Titan
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Jun 23 '26 |
Sale |
117.94 |
9,000 |
1,061,460 |
7,825 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):